Many highly-successful MBI graduates have made the leap from academia to industry. Nevertheless, the world of biotech, and the drug discovery pipeline in particular, can be a mystery. The MBI is working with researchers at Amgen to illuminate the process by which new drugs are developed, tested and brought to market.
This 5-day workshop, lead by Amgen researchers, will cover key aspects of the drug discovery process, including:
- Identifying therapeutic targets
- Increasing efficacy and safety
- Process development, devices and manufacturing
- Case studies from bench to clinic
The workshop will culminate with a site-visit to the Amgen campus in Thousand Oaks.
Space is very limited on the Amgen site visit. Registrants who attend all 4 days of the workshop at UCLA will be offered priority.
Jim Johnston Executive Director of Research
John Ferbas Director of the Cytometry Sciences Group
Chris Paszty Scientific Director in Cardiometabolic Disorders
Kevin Graham Biologics Optimization group within Therapeutic Discovery.
Ana Minatti leads a team of Medicinal Chemists working in the field of Cardiometabolic Disorders.
Graeme Moffat Executive Director, Preclinical
Winnie Sohn Principal Scientist in the Clinical Pharmacology, Modeling & Simulation group.
Paul Hughes Oncology Research group
Linda Narhi Scientific Executive Director in Process Development. Linda is also the director of the Amgen Postdoc Program and academic outreach.
Maria Victoria Silva Elipe NMR leader in structure elucidation in the Attribute Sciences Department
Monday- Thursday, March 26th-29th
Boyer Hall 159
Friday March 30th
Bus to Amgen leaves from UCLA, at 7.30am
Estimated return 2-2.30pm.